S100A11 and hepatocellular carcinoma: Peripheral blood assays were used for predicting immunotherapy response.<h4>Results</h4>A combined prognostic model integrating S100A11 and PUSL1 expression with clinical characteristics was constructed, and it effectively predicted survival in HCC patients.